Disturbances of anticoagulation and fibrinolytic systems in monoclonal gammopathies - Another mechanism of M-protein interference with hemostasis

Thrombosis Research

Volumn 112, Issue 5-6, 2003, Pages 297-300

  Spicka, Ivan ^a   Rihova, Zuzana ^a   Kvasnicka, Jan ^a   Cieslar, Petr ^a   Prochazka, Bohumir ^b   Klener, Pavel ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Antithrombin III; AT III; Fibrinolysis; MG; MIg; MM; Monoclonal gammopathy; Monoclonal immunoglobulin; Multiple myeloma; PA; PAI; PC; Plasminogen; Plasminogen activator(s); PLG; Protein C; Protein S; PS

Indexed keywords

ANTITHROMBIN III; APC; PARAPROTEIN; PLASMINOGEN; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MYELOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 1642324323     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.12.007     Document Type: Article

References (27)

1. Glaspy J.A. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol. Oncol. Clin. North Am. 6:1992;1301-1314.
2. Lackner H. Hemostatic abnormalities associated with dysproteinemias. Semin. Hematol. 10:1973;125-132.
3. Palmer R.N., Rick M.R., Rick P.D., Zeller J.A., Gralnick H.R. Circulating heparan sulfate anticoagulant in a patient with a fatal bleeding disorder. N. Engl. J. Med. 310:1984;1696-1699.
4. Robert F., Mignucci M., McCurdy S.A., Maldonado N., Lee J.Y. Hemostatic abnormalities associated with monoclonal gammopathies. Am. J. Med. Sci. 306:1993;359-366.
5. Perkins H.A., Mackenzie M.R., Fundenburg J.J. Hemostatic defects in dysproteinemias. Blood. 35:1970;695-707.
6. Carr M.E. Jr., Zekert S.L. Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am. J. Physiol. 266:1994;1195-1201.
7. Chapman G.S., George C.H.B., Danley D.L. Heparin-like anticoagulant associated with plasma cell myeloma. Am. J. Clin. Pathol. 83:1985;764-766.
8. Kasturi J., Saraya A.K. Platelet functions in dysproteinaemia. Acta Haematol. 59:1978;104-113.
9. Spicka I., Cieslar P., Dyr J.-E., Matousova O. Haemostasis abnormalities in monoclonal gammopathies. Sborník Lék. 93:1991;277-286.
10. Henstell H.H., Kligermann M. A new theory of interference with the clotting mechanism: the complexing of euglobulin with factor V, factor VII and prothrombin. Ann. Intern. Med. 49:1958;371-374.
11. Sanchez-Avalos J., Soong B.C.F., Miller S.P. Coagulation disorders in cancer: II. Multiple myeloma. Cancer. 23:1969;1388.
12. Scates S.M. Diagnosis and treatment of cancer-related thrombosis. Hematol Oncol. Clin. North Am. 6:1992;1329-1338.
13. Luzzatto G., Schafer A.I. The prethrombotic state in cancer. Semin. Oncol. 17:1990;147-159.
14. Colman R.W., Rubin R.N. Disseminated intravascular coagulation due to malignancy. Semin. Oncol. 17:1990;172-186.
15. Quitt M., Aghai E., David M., Kohan R., Ben Ari Y., Froom P. Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome. Scand. J. Haematol. 35:1985;155-157.
16. Thiagarajan P., Shapiro S.S., De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J. Clin. Invest. 66:1980;397-405.
17. Jorgensen K.A., Sorensen P., Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 68:1982;39-42.
18. Soria J., Soria C., Samama M. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and from studies of thrombolysis. Davidsonet al. Progress in chemical fibrinolysis and thrombolysis. vol. 3:1978;337-346 Raven, New York.
19. Patterson W.P., Ringenberg Q.S. The pathophysiology of thrombosis in cancer. Semin. Oncol. 17:1990;140-146.
20. Catovsky D., Ikoku N.B., Pitney W.R., Galton D.A.G. Thromboembolic complications in myelomatosis. Br. Med. J. 3:1970;438-439.
21. Talerman A. Thromboembolic complications in myelomatosis. Br. Med. J. 2:1970;709.
22. Thiagarajan P., Dannenbring R., Matsuura K.et al. Monoclonal antibody lithit chain with prothrombinase activity. Biochemistry. 39:2000;6459-6465.
23. Deitcher S.R., Erban J.K., Limentani S.A. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am. J. Hematol. 51:1996;319-323.
24. Vigliano E.M., Horowith H.I. Bleeding syndrome in a patient with IgA-myeloma: interaction of protein and connective tissue. Blood. 29:1967;823-836.
25. Perrin M.C., Jaubert J., Reynaud J., Mounier C., Oriol P., Guyotat D. High incidence of thrombotic events in myeloma patients. Br. J. Haematol. 102:1998;355. [Abstr.].
26. Zangari M., Siegel E., Barlogie B., Anaissie E., Saghafifar F., Fassas A.et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 100(4):2002 (Aug. 15);1168-1171.
27. Zangari M., Saghafifar F., Anaissie E., Badros A., Desikan R., Fassas A.et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul. Fibrinolysis. (3): 2002 (Apr. 13);187-192.